Efficacious and safe use of recombinant activated factor VII (rFVIIa) in patients with enoxaparin (ENOX)-induced bleeding and pre-existing hypercoagulable states

被引：1
|
作者：
Firozvi, K [1 ]
Acs, P [1 ]
Baidas, S [1 ]
Deveras, R [1 ]
Kessler, CM [1 ]
机构：
[1] Georgetown Univ, Ctr Med, Lombardi Canc Ctr, Washington, DC USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.1054.1054
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1054
引用
收藏
页码：300A / 300A
页数：1
相关论文
共 42 条
  • [31] A SYSTEMATIC REVIEW OF THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) IN THE ON-DEMAND TREATMENT OF MINOR TO MODERATE BLEEDING EPISODES FOR HAEMOPHILIA PATIENTS WITH INHIBITORS
    Knight, C.
    Dano, A. M.
    Kennedy-Martin, T.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A628 - A628
  • [32] Real-life use of activated recombinant Factor VII (rFVIIa) in elderly patients with haemophilia with inhibitors - data from the UK National Haemophilia Database
    Dolan, G.
    Bjerre, J.
    Hay, C. R. M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 980 - 981
  • [33] Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven®) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
    D Thabut
    R de Franchis
    F Bendtsen
    G D'Amico
    A Albillos
    JG Abraldes
    S Sofelt
    J Bosch
    [J]. Critical Care, 8 (Suppl 1):
  • [34] Efficacy of activated recombinant factor VII (rFVIIa; Novoseven®) in cirrhotic patients with upper gastrointestinal bleeding:: A randomized placebo-controlled double-blind multicenter trial
    Thabut, D
    De Franchis, R
    Bendtsen, F
    D'Amico, G
    Albillos, A
    Abraldes, JG
    Fabricius, S
    Bosch, J
    [J]. GASTROENTEROLOGY, 2003, 124 (04) : A697 - A697
  • [35] Efficacy of activated recombinant factor VII (rFVIIa; Novoseven®) in cirrhotic patients with upper gastrointestinal bleeding:: A randomised placebo-controlled double-blind multicenter trial
    Thabut, D
    de Franchis, R
    Bendtsen, F
    D'Amico, G
    Albillos, A
    Abraldes, JG
    Fabricius, S
    Bosch, J
    [J]. JOURNAL OF HEPATOLOGY, 2003, 38 : 13 - 13
  • [36] Use of Recombinant Activated Factor VII for Intractable Bleeding in Patients Without Hemophilia: A Developing Country Tertiary Care Center's Experience
    Musallam, Khaled M.
    Saad, George S. Abi
    Majdalani, Marianne N.
    Muwakkit, Samar A.
    Bou-Khalil, Pierre K.
    Aoun, Elie G.
    Sawaya, Raja A.
    Khalil, Ismail
    Taher, Ali T.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2010, 16 (06) : 658 - 662
  • [37] Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures
    Di Minno, Matteo Nicola Dario
    Ambrosino, Pasquale
    Myasoedova, Veronika
    Amato, Manuela
    Ventre, Itala
    Tremoli, Elena
    Di Minno, Alessandro
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (07) : 1125 - 1131
  • [38] Real-life use of high and standard initial doses of activated recombinant Factor VII (rFVIIa) in patients with haemophilia A and B with inhibitors - data from the UKHCDO/NHD registry
    Hay, C. R. M.
    Bjerre, J.
    Dolan, G.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 718 - 718
  • [39] The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings
    Lin, J
    Hanigan, WC
    Tarantino, M
    Wang, J
    [J]. JOURNAL OF NEUROSURGERY, 2003, 98 (04) : 737 - 740
  • [40] Use of recombinant activated factor VII for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia: A systematic review and meta-analysis of randomized controlled trials
    Chang, Zhigang
    Chu, Xin
    Liu, Yalin
    Liu, Dadong
    Feng, Zhe
    [J]. JOURNAL OF CRITICAL CARE, 2021, 62 : 164 - 171
12345